Clinical trial

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations…

NCT00203177 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed

Key facts

NCT number NCT00203177
Title Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Official title A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.
Lead sponsor Teva Branded Pharmaceutical Products R&D, Inc., Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Parkinson's Disease
Intervention type Drug
Interventions rasagiline mesylate, rasagiline mesylate 1.0 mg
Enrollment 254
Start date Oct 1, 2001
Primary completion Dec 1, 2006
First posted Sep 20, 2005
Last update posted Mar 9, 2010
Countries Canada, United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies